Liquidia's Profit Streak Continues
Liquidia Achieves Fourth Consecutive Profitable Quarter with $171.7M Q2 2026 Revenue
Key Points
Liquidia disclosed 89,508,891 shares of common stock outstanding as of July 29, 2026.
Commercialization of Sandoz's fully substitutable generic treprostinil injection is underway, using ICU Medical infusion pumps (CADD-MS 3, CADD Legacy, CADD-Solis) and a subcutaneous administration cartridge developed with Chengdu Shifeng Medical Technologies LTD.
Liquidia is involved in active patent litigation with United Therapeutics across multiple jurisdictions, including the U.S. District Court for the District of Delaware, the Middle District of North Carolina, and the Durham County Superior Court in North Carolina.
An August 12, 2026 Form 8-K filed with the SEC included a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2); the filing notes that information under Item 2.02 shall not be deemed filed for purposes of Section 18, and the form was signed by CFO Michael Kaseta.
Liquidia describes L606 as an investigational extended-release formulation of treprostinil delivered twice daily via a next-generation nebulizer.
Liquidia Corporation posted $171.7 million in total revenue for the second quarter of 2026, driven almost entirely by $170.4 million in net sales of its inhaled pulmonary hypertension drug YUTREPIA — a 31% jump from the prior quarter, according to Kalkine Media. The company earned $74.7 million in net income and $96.3 million in adjusted EBITDA, marking its fourth consecutive profitable quarter.
Cash and cash equivalents climbed to $284.2 million. Since YUTREPIA launched, more than 5,000 patients have used the drug, with roughly 5,900 prescriptions written by over 1,100 prescribers, per Kalkine Media.
YUTREPIA Sales Surge 1,840% Year Over Year
YUTREPIA's revenue growth is staggering on an annual basis. ScanX Trade reported the drug's sales surged 1,840% compared to the same quarter a year ago. Sequential growth of 31% shows the momentum is holding quarter after quarter, not just a one-time spike.
Yahoo Finance noted that Liquidia's Q2 results reflect a company that has moved firmly past the launch phase. The four straight profitable quarters signal that YUTREPIA has found a stable and growing patient base in the pulmonary arterial hypertension market.
Generic Treprostinil Injection Adds Another Revenue Stream
Beyond YUTREPIA, Liquidia is also commercializing a generic version of treprostinil injection through Sandoz. The product is fully substitutable for the branded version. It uses ICU Medical infusion pumps — including the CADD-MS 3, CADD Legacy, and CADD-Solis models — and a subcutaneous cartridge developed with Chengdu Shifeng Medical Technologies, according to Kalkine Media.
This generic adds a second commercial product to Liquidia's portfolio. It broadens the company's reach in the treprostinil market, giving it a foothold in both inhaled and injectable delivery of the drug.
Pipeline Drug L606 Targets Next-Generation Delivery
Liquidia is developing L606, an investigational drug that delivers treprostinil in an extended-release form twice a day through a next-generation nebulizer. The company sees L606 as a potential improvement over current inhaled therapies, per Kalkine Media. Clinical studies are ongoing.
Development timelines and regulatory considerations for L606 were discussed during the company's Q2 earnings update. CFO Michael Kaseta signed the August 12, 2026 Form 8-K filed with the SEC, which included both the earnings press release and an updated investor presentation.
Patent Fight With United Therapeutics Continues on Multiple Fronts
Liquidia remains locked in active patent litigation with United Therapeutics, the maker of branded treprostinil products. The legal battle spans three venues: the U.S. District Court in Delaware, the Middle District of North Carolina, and the Durham County Superior Court in North Carolina, according to Kalkine Media.
The outcome of this litigation could shape Liquidia's long-term market position. As of July 29, 2026, the company had 89,508,891 shares of common stock outstanding. Market Screener confirmed the six-month revenue figure through June 30, 2026 stood at $8.84 million on a comparable prior-year basis, underscoring how rapidly the business has scaled.
Sentiment
Mostly PositivePublishers
17
Articles
29
Reach
46
